Search Medical Condition
Please enter condition
Please choose location from dropdown

Shanxi Province, China Clinical Trials

A listing of Shanxi Province, China clinical trials actively recruiting patients volunteers.

RESULTS

Found (5) clinical trials

Study of Efficacy and Safety of Secukinumab in Patients With Ankylosing Spondylitis

To demonstrate the clinical efficacy, safety and tolerability of secukinumab compared to placebo in patients with ankylosing spondylitis at Week 16 and long term efficacy and safety up to Week 52.

Phase

0.0 miles

Learn More »

The Efficacy Assessment of Intravitreal Injection of Conbercept in Patients With Polypoidal Choroidal Vasculopathy (PCV)

To assess the efficacy of intravitreal injection of 0.5 mg conbercept in patients with polypoidal choroidal vasculopathy (PCV) and explore the optimal route of administration.

Phase

0.0 miles

Learn More »

Phenobarbital Versus Valproate for Generalized Convulsive Status Epilepticus

After the failure of first-line diazepam treatment, patients with GCSE are randomized to receive either IV PB (standard doses, low rate) or VPA (standard). Successful treatment is considered when clinical and electroencephalographic seizure activity ceases. Adverse events following treatment and the neurological outcomes at discharge and 3 months later are ...

Phase

0.0 miles

Learn More »

Syndrome Differentiation in the Management of Chronic Stable Coronary Artery Disease (SCAD) to Improve Quality

Chronic stable coronary artery disease (SCAD) is a general term for all kinds of coronary artery disease (CAD) which includes patients with chronic stable angina, oldmyocardial infarctions and also stable condition after revascularization (i.e percutaneous coronary intervention PCI, coronary artery bypass graft CABG). According to 2012 American Heart Association/American College ...

Phase N/A

0.0 miles

Learn More »

Remote Ischemic Conditioning for Avoiding Recurrence of Symptomatic Intracranial Atherosclerotic Stenosis (sICAS)

In this study, Patients in the RLIC group will be treated with Renqiao Remote Ischemic Conditioning Device (Doctormate) (200mmHg) once daily for 12 months; patients in the sham RLIC group will be treated with the Renqiao Remote Ischemic Conditioning Device (Doctormate) (60mmHg) once daily for 12 months. In the study, ...

Phase N/A

4.96 miles

Learn More »